CWP232228

Research use only, not for human use.

CWP232228, a potent and selective Wnt / β-catenin signaling inhibitor, antagonizes the binding of β-catenin to T-cell factor (TCF) in the nucleus.

CWP232228, a potent and selective Wnt / β-catenin signaling inhibitor, antagonizes the binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 inhibits the formation and metastasis of tumors by inhibiting the growth of breast cancer and liver cancer stem cells (CSC) without toxicity.(In Vitro):CWP232228 (0.01-100 μM; 48 hours) inhibited cell proliferation, and IC50 values in mouse (4T1) and human (MDA-MB-435) breast cancer cell lines were 2 and 0.8 μM, respectively. CWP232228 (0.01-10 μM; 48 hours) inhibited cell proliferation in Hep3B, Huh7 and HepG2 cells with IC50 of 2.566, 2.630 and 2.596 μM, respectively.(In Vivo):CWP232228 (100 mg/kg, administered i.p.; daily; mice with 4T1 cell tumors for 21 days; mice with MDA-MB-435 cell tumors for 60 days) resulted in a significant reduction in tumor volume.

CWP232228 (0.01-100 μM; 48 hours) inhibits cell proliferation with IC50 values are 2 and 0.8 μM in mouse (4T1) and human (MDA-MB-435) breast cancer cell lines, respectively.CWP232228 (0.01-10 μM; 48 hours) inhibits cell proliferation with IC50s of 2.566, 2.630, and 2.596 μM in Hep3B, Huh7 and HepG2 cells, respectively. Cell Proliferation Assay Cell Line:Mouse (4T1) and human (MDA-MB-435) breast cancer cell lines Concentration:0.01, 0.1, 1, 10, 100 μM Incubation Time:48 hours Result:IC50s were 2 and 0.8 μM for 4T1 and MDA-MB-435 cell lines, respectively.Cell Proliferation Assay Cell Line:Hepatocellular carcinoma cell lines HepG2, Huh7, and Hep3B Concentration: 0.01, 0.1, 0.5, 1, 5, 10 μM Incubation Time:48 hours Result:IC50s were 2.566, 2.630, and 2.596 μM for Hep3B, Huh7 and HepG2 cells, respectively.

CWP232228 (100 mg/kg, administered i.p.; daily; 21days for mice bearing 4T1 cell tumors; 60 days for mice bearing MDA-MB-435 cell tumors) results in a significant reduction in tumor volume. Animal Model:7-week-old female Balb/c and NOD/SCID mice bearing 4T1 or MDA-MB-435 cell tumors Dosage:100 mg/kg Administration:Administered i.p.; daily; 21days for mice bearing 4T1 cell tumors, 60 days for mice bearing MDA-MB-435 cell tumors Result:Treatment resulted in a significant reduction in tumor volume.

——

Wnt/Notch/Hedgehog

Wnt/beta/catenin

——

——

——

1144044-02-9

717.63

C33H34N7Na2O7P

>98% (HPLC)

In Vitro:?H2O : 62.5 mg/mL (87.09 mM)

Cn1cc2cccc(CN3C[C@@H]4N(N(CC=C)CC(=O)N4[C@@H](Cc4ccc(OP(=O)(O[Na])O[Na])cc4)C3=O)C(=O)NCc3ccccc3)c2n1

——

(-20℃)

With Ice Pack

≥ 2 years